{{Distinguish | Dextromethorphan | Dextrorphan | 3-Methoxymorphinan}}
{{Drugbox
| Verifiedfields = changed
| Watchedfields = changed
| verifiedrevid = 462091038
| IUPAC_name = (1''R'',9''R'',10''R'')-4-methoxy-17-methyl-17-azatetracyclo[7.5.3.0¹,¹⁰.0²,⁷]heptadeca-2(7),3,5-triene
| image = Levomethorphan.svg
| image2 = Levometorfan.png

<!--Clinical data-->
| tradename =  
| MedlinePlus = 
| pregnancy_AU = <!-- A / B1 / B2 / B3 / C / D / X -->
| pregnancy_US = <!-- A / B / C / D / X -->
| legal_AU = S9
| legal_CA = Schedule I
| legal_US = Schedule II
| legal_UK = Class A
| legal_DE = Anlage I

<!--Pharmacokinetic data-->
| elimination_half-life = 3-6 hours

<!--Identifiers-->
| CAS_number_Ref = {{cascite|changed|??}}
| CAS_number = 125-70-2
| ATC_prefix = None
| PubChem = 5362449
| DrugBank_Ref = {{drugbankcite|changed|drugbank}}
| DrugBank = 
| ChemSpiderID_Ref = {{chemspidercite|correct|chemspider}}
| ChemSpiderID = 4642423
| UNII_Ref = {{fdacite|correct|FDA}}
| UNII = 7ZZ22K9QE6
| ChEBI_Ref = {{ebicite|changed|EBI}}
| ChEBI = 
| ChEMBL_Ref = {{ebicite|changed|EBI}}
| ChEMBL = 1908323

<!--Chemical data-->
| C=18 | H=25 | N=1 | O=1 
| molecular_weight = 271.397 g/mol
| smiles = COc1ccc2C[C@@H]3[C@@H]4CCCC[C@]4(CCN3C)c2c1
| StdInChI_Ref = {{stdinchicite|correct|chemspider}}
| StdInChI = 1S/C18H25NO/c1-19-10-9-18-8-4-3-5-15(18)17(19)11-13-6-7-14(20-2)12-16(13)18/h6-7,12,15,17H,3-5,8-11H2,1-2H3/t15-,17+,18+/m0/s1
| StdInChIKey_Ref = {{stdinchicite|correct|chemspider}}
| StdInChIKey = MKXZASYAUGDDCJ-CGTJXYLNSA-N
}}

'''Levomethorphan''' ([[International Nonproprietary Name|INN]], [[British Approved Name|BAN]]) is an [[opioid]] [[analgesic]] of the [[morphinan]] family that has never been marketed.<ref name="Elks2014">{{cite book|author=J. Elks|title=The Dictionary of Drugs: Chemical Data: Chemical Data, Structures and Bibliographies|url=https://books.google.com/books?id=0vXTBwAAQBAJ&pg=PA656|date=14 November 2014|publisher=Springer|isbn=978-1-4757-2085-3|pages=656–}}</ref> It is the <small>L</small>-[[stereoisomer]] of [[racemethorphan]] (methorphan).<ref name="Elks2014" /> The effects of the two [[isomer]]s of the racemethorphan are quite different, with [[dextromethorphan]] (DXM) contrarily being an [[antitussive]] at low doses and a [[dissociative]] [[hallucinogen]] at much higher doses.<ref name="Hornback2005">{{cite book|author=Joseph M. Hornback|title=Organic Chemistry|url=https://books.google.com/books?id=FETzRWMGt3YC&pg=PA243|date=31 January 2005|publisher=Cengage Learning|isbn=0-534-38951-1|pages=243–}}</ref> It is about five times stronger than morphine. <ref>[https://books.google.fi/books?id=3qjUKyL7BokC&pg=PA21&lpg=PA21&dq=Levomethorphan+potent+morphine&source=bl&ots=rHxOGAnHwu&sig=0ii5X6BFjpVGRlhpXcf-kfeFB88&hl=fi&sa=X&ved=0ahUKEwiegNGm54fRAhXEWiwKHfX7Dz0Q6AEILTAD#v=onepage&q=Levomethorphan%20potent%20morphine&f=false Handbook of Analytical Therapeutic Drug Monitoring and Toxicology] Google books preview</ref>

Levomethorphan is a [[prodrug]] to [[levorphanol]], analogously to DXM acting as a prodrug to [[dextrorphan]] or [[codeine]] behaving as a prodrug to [[morphine]].<ref name="GudinFudin2015">{{cite journal|last1=Gudin|first1=Jeffrey|last2=Fudin|first2=Jeffrey|last3=Nalamachu|first3=Srinivas|title=Levorphanol use: past, present and future|journal=Postgraduate Medicine|volume=128|issue=1|year=2015|pages=46–53|issn=0032-5481|doi=10.1080/00325481.2016.1128308}}</ref> As such, levomethorphan has similar effects to levorphanol but is less potent as it must be demethylated to the active form by [[liver]] [[enzyme]]s before being able to produce its effects.<ref name="GudinFudin2015" /> As a prodrug of levorphanol, levomethorphan functions as a potent [[agonist]] of all three of the [[opioid receptor]]s, [[μ-opioid receptor|μ]], [[κ-opioid receptor|κ]] (κ<sub>1</sub> and κ<sub>3</sub> but notably not κ<sub>2</sub>), and [[δ-opioid receptor|δ]], as an [[NMDA receptor antagonist]], and as a [[serotonin-norepinephrine reuptake inhibitor]].<ref name="GudinFudin2015" /> Via activation of the KOR, levomethorphan can produce [[dysphoria]] and [[psychotomimetic]] effects such as [[dissociation (psychology)|dissociation]] and [[hallucination]]s.<ref name="BrueraPortenoy2009">{{cite book|author1=Eduardo D. Bruera|author2=Russell K. Portenoy|title=Cancer Pain: Assessment and Management|url=https://books.google.com/books?id=2TJ-_oECXM4C&pg=PA215|date=12 October 2009|publisher=Cambridge University Press|isbn=978-0-521-87927-9|pages=215–}}</ref>

Levomethorphan is listed under the Single Convention on Narcotic Drugs 1961 and is regulated like [[morphine]] in most countries. In the United States it is a Schedule II Narcotic controlled substance with a DEA ACSCN of 9210 and 2014 annual aggregate manufacturing quota of 195 grammes, up from 6 grammes the year before. The salts in use are the tartrate (free base conversion ratio 0.644) and hydrobromide (0.958).<ref>http://www.deadiversion.usdoj.gov/quotas/conv_factor/index.html</ref> At the current time, no levomethorphan pharmaceuticals are marketed in the United States.

==See also==
* [[Butorphanol]]
* [[Cyclorphan]]
* [[Levallorphan]]
* [[Levorphanol]]
* [[Nalbuphine]]
* [[Oxilorphan]]
* [[Proxorphan]]
* [[Racemorphan]]
* [[Xorphanol]]

==References==
{{Reflist|2}}


{{Analgesics}}
{{Hallucinogens}}
{{Analgesics}}
{{Navboxes
| title = [[Pharmacodynamics]]
| titlestyle = background:#ccccff
| list1 = 
{{GABA receptor modulators}}
{{Glycine receptor modulators}}
{{Ionotropic glutamate receptor modulators}}
{{Monoamine reuptake inhibitors}}
{{Opioid receptor modulators}}
}}

[[Category:Delta-opioid agonists]]
[[Category:Dissociative drugs]]
[[Category:Enantiopure drugs]]
[[Category:GABA receptor antagonists]]
[[Category:Glycine receptor antagonists]]
[[Category:Kappa agonists]]
[[Category:NMDA receptor antagonists]]
[[Category:Morphinans]]
[[Category:Mu-opioid agonists]]
[[Category:Nociceptin receptor agonists]]
[[Category:Phenol ethers]]
[[Category:Prodrugs]]
[[Category:Semisynthetic opioids]]
[[Category:Serotonin-norepinephrine reuptake inhibitors]]


{{analgesic-stub}}